ALLMedicine™ Alopecia Center

Sep 15th, 2021 - Although dissecting cellulitis (DC) and hidradenitis suppurativa (HS) are classified separately, they share many clinical, dermatoscopic, pathogenetic, and histologic aspects, as well as therapeutic options. The association between DC, HS, and acn...

Sep 13th, 2021 - Folliculitis decalvans (FD) is a neutrophilic primary cicatricial alopecia (CA) affecting mostly middle-aged males. Key features include confluent areas of CA, surrounded by polytrichia (tufted hairs), pustules and crusting mainly over the vertex ...

Sep 10th, 2021 - Androgenetic alopecia (AGA) is a prevalent condition with a complex etiopathogenesis. Angiotensin-converting enzyme (ACE) gene located on the chromosome 17q23 contains an insertion (I) and deletion (D) polymorphism in the intron 16. This gene poly...

Sep 9th, 2021 - Permanent chemotherapy-induced alopecia (pCIA), for which preventive interventions remain limited, can manifest with scarring. While the underlying pathomechanisms of pCIA are unclear, depletion of epithelial hair follicle (HF) stem cells (eHFSCs)...

Sep 7th, 2021 - Incidence and comorbidities of pediatric alopecia areata: a retrospective matched cohort study using the Rochester Epidemiology Project.|2021|Ali NS,Tollefson MM,Lohse CM,Torgerson RR,|

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

Aug 23rd, 2021 - Alpopecia Areata (AA) is the second common cause of non-scarring hair loss, the disease has huge negative impact on patients' quality of life, social and psychological status. The underlying pathogenesis of AA is not fully characterized, Yet the c...

Jul 16th, 2021 - The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 3 different dosing regim...

Apr 21st, 2021 - This will be a trial evaluating the efficacy of micro-needling via tattoo device in stimulating scalp hair growth in patients with AA refractory to combination JAK inhibitor and oral minoxidil treatment. Ten healthy subjects who are at least eight...

Apr 10th, 2014 - This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion...

Feb 27th, 2014 - The most common type of hair loss is androgenetic alopecia (AGA), also known as male pattern balding, or hereditary thinning. In AGA, there is a gradual transformation of large terminal hair follicles to miniaturized ones under the influence of ci...

Aug 17th, 2021 - Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA app...

Jul 16th, 2021 - The prevalence of pediatric alopecia areata (AA) in the United States has increased twofold over the past decade and it disproportionately affects females and Hispanic children, according to results from the largest study to date on the topic. "Al...

Jul 9th, 2021 - The FDA has granted a regular approval to enfortumab vedotin-ejfv (Padcev) and has expanded the agent's indication to include adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemothe...

May 8th, 2021 - The differentiated TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (DS-1062a) was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer (TN...

Apr 28th, 2021 - This article originally appeared on the Hospital for Special Surgery's website. Case Report A 45-year-old woman with a history of systemic lupus erythematosus (SLE) since 2006 came to the Hospital for Special Surgery in 2014 for continued manageme...